دورية أكاديمية
Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.
| العنوان: | Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. |
|---|---|
| المؤلفون: | Daly, Aideen B, Boughton, Charlotte K, Nwokolo, Munachiso, Hartnell, Sara, Wilinska, Malgorzata E, Cezar, Alina, Evans, Mark L, Hovorka, Roman |
| بيانات النشر: | Springer Science and Business Media LLC //dx.doi.org/10.1038/s41591-022-02144-z Nat Med |
| سنة النشر: | 2023 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | Male, Humans, Adult, Female, Middle Aged, Aged, Insulin, Blood Glucose, Cross-Over Studies, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Type 1, Treatment Outcome, Insulin Infusion Systems, Hypoglycemia |
| الوصف: | Funder: Dexcom supplied discounted continuous glucose monitoring devices and sensors for the study; company representatives had no role in the study conduct. Supported by National Institute for Health and Care Research Cambridge Biomedical Research Centre. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. ; Funder: The University of Cambridge has received salary support for MLE from the National Health Service in the East of England through the Clinical Academic Reserve. ; In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. In an open-label, single-center, randomized crossover study, 26 adults with type 2 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 ± 11 years; baseline glycated hemoglobin (HbA1c), 75 ± 15 mmol mol-1 (9.0% ± 1.4%)) underwent two 8-week periods to compare the CamAPS HX fully closed-loop app with standard insulin therapy and a masked glucose sensor (control) in random order, with a 2-week to 4-week washout between periods. The primary endpoint was proportion of time in target glucose range (3.9-10.0 mmol l-1). Analysis was by intention to treat. Thirty participants were recruited between 16 December 2020 and 24 November 2021, of whom 28 were randomized to two groups (14 to closed-loop therapy first and 14 to control therapy first). Proportion of time in target glucose range (mean ± s.d.) was 66.3% ± 14.9% with closed-loop therapy versus 32.3% ± 24.7% with control therapy (mean difference, 35.3 percentage points; 95% confidence interval (CI), 28.0-42.6 percentage points; P < 0.001). Time > 10.0 mmol l-1 was 33.2% ± 14.8% with closed-loop therapy versus 67.0% ± 25.2% with control therapy (mean difference, -35.2 percentage points; 95% CI, -42.8 to -27.5 percentage points; P < 0.001). Mean glucose was lower during the closed-loop therapy period than during the control therapy period (9.2 ± 1.2 mmol l-1 versus 12.6 ± 3.0 ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf; text/xml; application/zip |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/345753Test |
| DOI: | 10.17863/CAM.93174 |
| الإتاحة: | https://doi.org/10.17863/CAM.93174Test https://www.repository.cam.ac.uk/handle/1810/345753Test |
| رقم الانضمام: | edsbas.F8565CE1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17863/CAM.93174 |
|---|